Avoiding Antibiotic Inactivation in Mycobacterium tuberculosis by Rv3406 through Strategic Nucleoside Modification

Matthew R. Bockman; Curtis A. Engelhart; Surendra Dawadi; Peter Larson; Divya Tiwari; David M. Ferguson; Dirk Schnappinger; Courtney C. Aldrich

doi:10.1021/acsinfecdis.8b00038

Avoiding Antibiotic Inactivation in Mycobacterium tuberculosis by Rv3406 through Strategic Nucleoside Modification

Matthew R. Bockman, Curtis A. Engelhart, Surendra Dawadi, Peter Larson, Divya Tiwari, David M. Ferguson, Dirk Schnappinger, Courtney C. Aldrich

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

5′-[N-(d-biotinoyl)sulfamoyl]amino-5′-deoxyadenosine (Bio-AMS, 1) possesses selective activity against Mycobacterium tuberculosis (Mtb) and arrests fatty acid and lipid biosynthesis through inhibition of the Mycobacterium tuberculosis biotin protein ligase (MtBPL). Mtb develops spontaneous resistance to 1 with a frequency of at least 1 × 10^-7 by overexpression of Rv3406, a type II sulfatase that enzymatically inactivates 1. In an effort to circumvent this resistance mechanism, we describe herein strategic modification of the nucleoside at the 5′-position to prevent enzymatic inactivation. The new analogues retained subnanomolar potency to MtBPL (K_D = 0.66-0.97 nM), and 5′R-C-methyl derivative 6 exhibited identical antimycobacterial activity toward: Mtb H37Rv, MtBPL overexpression, and an isogenic Rv3406 overexpression strain (minimum inhibitory concentration, MIC = 1.56 μM). Moreover, 6 was not metabolized by recombinant Rv3406 and resistant mutants to 6 could not be isolated (frequency of resistance <1.4 × 10^-10) demonstrating it successfully overcame Rv3406-mediated resistance.

Original language	English (US)
Pages (from-to)	1102-1113
Number of pages	12
Journal	ACS Infectious Diseases
Volume	4
Issue number	7
DOIs	https://doi.org/10.1021/acsinfecdis.8b00038
State	Published - Jul 13 2018

Bibliographical note

Funding Information:
This work was supported by a grant (AI091790 to D.S.) from the National Institutes of Health as well as the University of Minnesota Bighley Fellowship. Isothermal titration calorimetry was carried out using an ITC-200 microcalorimeter, funded by the NIH Shared Instrumentation Grant S10-OD017982. Mass spectrometry was carried out in the Center for Mass Spectrometry and Proteomics, University of Minnesota. We also gratefully acknowledge Bruce Witthuhn for his contributions and assistance using the LC-MS/MS instruments. We also thank Carolyn Bertozzi for providing the Rv3406 over-expression plasmid. Finally, we acknowledge the Minnesota Supercomputing Institute (MSI) at the University of Minnesota for providing resources that contributed to the research results reported within this paper (http://www.msi.umn.edu).

Publisher Copyright:
Copyright © 2018 American Chemical Society.

Keywords

Mycobacterium tuberculosis
adenylation
biotin protein ligase
bisubstrate inhibitor
metabolism
tuberculosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1021/acsinfecdis.8b00038

Find It

Find It at U of M Libraries

Cite this

@article{03c4bc00ae5b4044a792b43f64e3692a,

title = "Avoiding Antibiotic Inactivation in Mycobacterium tuberculosis by Rv3406 through Strategic Nucleoside Modification",

abstract = "5′-[N-(d-biotinoyl)sulfamoyl]amino-5′-deoxyadenosine (Bio-AMS, 1) possesses selective activity against Mycobacterium tuberculosis (Mtb) and arrests fatty acid and lipid biosynthesis through inhibition of the Mycobacterium tuberculosis biotin protein ligase (MtBPL). Mtb develops spontaneous resistance to 1 with a frequency of at least 1 × 10-7 by overexpression of Rv3406, a type II sulfatase that enzymatically inactivates 1. In an effort to circumvent this resistance mechanism, we describe herein strategic modification of the nucleoside at the 5′-position to prevent enzymatic inactivation. The new analogues retained subnanomolar potency to MtBPL (KD = 0.66-0.97 nM), and 5′R-C-methyl derivative 6 exhibited identical antimycobacterial activity toward: Mtb H37Rv, MtBPL overexpression, and an isogenic Rv3406 overexpression strain (minimum inhibitory concentration, MIC = 1.56 μM). Moreover, 6 was not metabolized by recombinant Rv3406 and resistant mutants to 6 could not be isolated (frequency of resistance <1.4 × 10-10) demonstrating it successfully overcame Rv3406-mediated resistance.",

keywords = "Mycobacterium tuberculosis, adenylation, biotin protein ligase, bisubstrate inhibitor, metabolism, tuberculosis",

author = "Bockman, {Matthew R.} and Engelhart, {Curtis A.} and Surendra Dawadi and Peter Larson and Divya Tiwari and Ferguson, {David M.} and Dirk Schnappinger and Aldrich, {Courtney C.}",

note = "Funding Information: This work was supported by a grant (AI091790 to D.S.) from the National Institutes of Health as well as the University of Minnesota Bighley Fellowship. Isothermal titration calorimetry was carried out using an ITC-200 microcalorimeter, funded by the NIH Shared Instrumentation Grant S10-OD017982. Mass spectrometry was carried out in the Center for Mass Spectrometry and Proteomics, University of Minnesota. We also gratefully acknowledge Bruce Witthuhn for his contributions and assistance using the LC-MS/MS instruments. We also thank Carolyn Bertozzi for providing the Rv3406 over-expression plasmid. Finally, we acknowledge the Minnesota Supercomputing Institute (MSI) at the University of Minnesota for providing resources that contributed to the research results reported within this paper (http://www.msi.umn.edu). Publisher Copyright: Copyright {\textcopyright} 2018 American Chemical Society.",

year = "2018",

month = jul,

day = "13",

doi = "10.1021/acsinfecdis.8b00038",

language = "English (US)",

volume = "4",

pages = "1102--1113",

journal = "ACS Infectious Diseases",

issn = "2373-8227",

publisher = "American Chemical Society",

number = "7",

}

TY - JOUR

T1 - Avoiding Antibiotic Inactivation in Mycobacterium tuberculosis by Rv3406 through Strategic Nucleoside Modification

AU - Bockman, Matthew R.

AU - Engelhart, Curtis A.

AU - Dawadi, Surendra

AU - Larson, Peter

AU - Tiwari, Divya

AU - Ferguson, David M.

AU - Schnappinger, Dirk

AU - Aldrich, Courtney C.

N1 - Funding Information: This work was supported by a grant (AI091790 to D.S.) from the National Institutes of Health as well as the University of Minnesota Bighley Fellowship. Isothermal titration calorimetry was carried out using an ITC-200 microcalorimeter, funded by the NIH Shared Instrumentation Grant S10-OD017982. Mass spectrometry was carried out in the Center for Mass Spectrometry and Proteomics, University of Minnesota. We also gratefully acknowledge Bruce Witthuhn for his contributions and assistance using the LC-MS/MS instruments. We also thank Carolyn Bertozzi for providing the Rv3406 over-expression plasmid. Finally, we acknowledge the Minnesota Supercomputing Institute (MSI) at the University of Minnesota for providing resources that contributed to the research results reported within this paper (http://www.msi.umn.edu). Publisher Copyright: Copyright © 2018 American Chemical Society.

PY - 2018/7/13

Y1 - 2018/7/13

N2 - 5′-[N-(d-biotinoyl)sulfamoyl]amino-5′-deoxyadenosine (Bio-AMS, 1) possesses selective activity against Mycobacterium tuberculosis (Mtb) and arrests fatty acid and lipid biosynthesis through inhibition of the Mycobacterium tuberculosis biotin protein ligase (MtBPL). Mtb develops spontaneous resistance to 1 with a frequency of at least 1 × 10-7 by overexpression of Rv3406, a type II sulfatase that enzymatically inactivates 1. In an effort to circumvent this resistance mechanism, we describe herein strategic modification of the nucleoside at the 5′-position to prevent enzymatic inactivation. The new analogues retained subnanomolar potency to MtBPL (KD = 0.66-0.97 nM), and 5′R-C-methyl derivative 6 exhibited identical antimycobacterial activity toward: Mtb H37Rv, MtBPL overexpression, and an isogenic Rv3406 overexpression strain (minimum inhibitory concentration, MIC = 1.56 μM). Moreover, 6 was not metabolized by recombinant Rv3406 and resistant mutants to 6 could not be isolated (frequency of resistance <1.4 × 10-10) demonstrating it successfully overcame Rv3406-mediated resistance.

AB - 5′-[N-(d-biotinoyl)sulfamoyl]amino-5′-deoxyadenosine (Bio-AMS, 1) possesses selective activity against Mycobacterium tuberculosis (Mtb) and arrests fatty acid and lipid biosynthesis through inhibition of the Mycobacterium tuberculosis biotin protein ligase (MtBPL). Mtb develops spontaneous resistance to 1 with a frequency of at least 1 × 10-7 by overexpression of Rv3406, a type II sulfatase that enzymatically inactivates 1. In an effort to circumvent this resistance mechanism, we describe herein strategic modification of the nucleoside at the 5′-position to prevent enzymatic inactivation. The new analogues retained subnanomolar potency to MtBPL (KD = 0.66-0.97 nM), and 5′R-C-methyl derivative 6 exhibited identical antimycobacterial activity toward: Mtb H37Rv, MtBPL overexpression, and an isogenic Rv3406 overexpression strain (minimum inhibitory concentration, MIC = 1.56 μM). Moreover, 6 was not metabolized by recombinant Rv3406 and resistant mutants to 6 could not be isolated (frequency of resistance <1.4 × 10-10) demonstrating it successfully overcame Rv3406-mediated resistance.

KW - Mycobacterium tuberculosis

KW - adenylation

KW - biotin protein ligase

KW - bisubstrate inhibitor

KW - metabolism

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85049850152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049850152&partnerID=8YFLogxK

U2 - 10.1021/acsinfecdis.8b00038

DO - 10.1021/acsinfecdis.8b00038

M3 - Article

C2 - 29663798

AN - SCOPUS:85049850152

SN - 2373-8227

VL - 4

SP - 1102

EP - 1113

JO - ACS Infectious Diseases

JF - ACS Infectious Diseases

IS - 7

ER -

Avoiding Antibiotic Inactivation in Mycobacterium tuberculosis by Rv3406 through Strategic Nucleoside Modification

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this